KEDI Global Obesity Care Industry Top 2+ Index

Q2 2026 earnings release on 2026-08-04 with analyst EPS forecast of $0.43; low importance estimated due to no current market impact, expected.

Second quarter 2026 financial results for 2026-07-21; low importance estimated as the date is a routine reporting event with an expected impact of approximately 1% scheduled.

Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.

FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.

Quarterly dividend of $0.85 per share has an ex-dividend date of June 15, 2026, scheduled.

Ex-dividend date for a quarterly cash dividend of $1.25 per share on 2026-06-12. The dividend was declared on May 26, 2026, and is payable on June 26, 2026. A price impact of approximately 1% is expected based on the dividend amount.

Novo Nordisk to host an R&D investor event to discuss data from the ADA 2026 Scientific Sessions, including Phase 3 results for CagriSema on 2026-06-07; High importance is estimated as Phase 3 data for key pipeline assets typically drives >10% price movement, scheduled.

Lululemon announced Q1 2026 financial results beating expectations but significantly lowered full-year 2026 guidance; analysts forecast a price impact of >=10% due to the substantial guidance cut, expected.

Published on 2026-06-04 final Phase III results for Vanrafia in The Lancet. Low importance estimated as the positive data supports existing market expectations, with an expected impact of approximately 1%.

Presented new Phase 3 data for UPLIZNA at the EULAR 2026 Congress, showing a 0% flare rate over one year in patients with IgG4-Related Disease who continued treatment. Medium importance as positive clinical data supports market share, expected.

Announced on 2026-06-03 plans to halve its €2.3 billion investment in a new German plant; medium impact estimated due to regulatory headwinds and reduced growth capacity, expected.

Novo Nordisk to launch the Wegovy pill in the United Arab Emirates on 2026-06-03; Medium importance is estimated as new market entries for blockbuster drugs typically impact price by >=5%, scheduled.

Presented positive final results from the Phase III SERENA-6 trial for camizestrant in breast cancer at the ASCO 2026 Annual Meeting, showing a 37% reduction in risk of second disease progression or death. High importance estimated due to significant clinical success in a major indication.

RBC Capital maintained its Outperform rating and raised its price target to $43.00 from $38.00; medium importance estimated based on significant price target increase, analysts forecasted.

European Commission granted marketing authorization for IMDYLLTRA (tarlatamab) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. High importance due to major drug approval potential, expected.

Announced that the CARES Phase III clinical program for anselamimab, a treatment for light chain amyloidosis, did not meet its primary endpoint in the overall patient population. High importance estimated due to the failure of a late-stage clinical trial.

Announced on June 1, 2026, that the Phase 3 LITESPARK-012 study of a Keytruda-based triplet therapy in first-line advanced clear cell renal cell carcinoma (RCC) did not meet its primary endpoints.

Received FDA Breakthrough Therapy designation for calderasib (MK-1084) on May 29, 2026. Medium importance as this designation accelerates the development of a key oncology candidate.